

Contents

List of contributors	xi
Acknowledgements	xiii
1 Introduction	1
<i>Anne Bridgen</i>	
1.1 Background	1
1.2 Reverse genetics for different classes of genome	2
1.3 Methodology	5
1.4 Difficulties in establishing a reverse genetics system	11
1.5 Recent developments	13
1.6 Are there any boundaries for conducting reverse genetics?	13
References	15
Part I Positive sense RNA viruses	25
2 Coronavirus reverse genetics	27
<i>Maria Armesto, Kirsten Bentley, Erica Bickerton, Sarah Keep and Paul Britton</i>	
2.1 The <i>Coronavirinae</i>	27
2.2 Infectious bronchitis	28
2.3 Coronavirus genome organisation	29
2.4 The coronavirus replication cycle	30
2.5 Development of reverse genetics system for coronaviruses including IBV	33
2.6 Reverse genetics system for IBV	37
2.7 Reverse genetics systems for the modification of coronavirus genomes	40
2.8 Using coronavirus reverse genetics systems for gene delivery	49
Acknowledgements	51
References	51
3 Reverse genetic tools to study hepatitis C virus	64
<i>Alexander Ploss</i>	
3.1 Introduction: hepatitis C	64
3.2 Hepatitis C virus	65
3.3 Construction of infectious clones for hepatitis C virus	68
3.4 Study of HCV RNA replication in cell culture systems	68

3.5	Use of HCV replicons to study viral replication	70
3.6	Utility of replicons for drug screening	71
3.7	Development of the infectious cell culture systems for HCV	71
3.8	Construction of intergenotypic viral chimeras	72
3.9	Non-JFH1 derived genomes	74
3.10	Cell lines that support HCV replication	74
3.11	Study of HCV in physiologically more relevant cell culture systems	75
3.12	Animal models for HCV infection	76
3.13	Reverse genetics of clinically relevant HCV genotypes <i>in vivo</i>	77
3.14	Conclusion	78
	Acknowledgments	78
	References	78
4	Calicivirus reverse genetics	91
	<i>Ian Goodfellow</i>	
4.1	Introduction	91
4.2	Feline calicivirus	93
4.3	Murine norovirus	97
4.4	Porcine enteric calicivirus	103
4.5	Rabbit haemorrhagic disease virus	104
4.6	Human norovirus	104
4.7	Conclusion	106
	Acknowledgements	107
	References	107
Part II	Negative sense RNA viruses	113
5	Reverse genetics of rhabdoviruses	115
	<i>Alexander Ghanem and Karl-Klaus Conzelmann</i>	
5.1	Introduction: the <i>Rhabdoviridae</i> family	115
5.2	Rhabdovirus reverse genetics	121
5.3	Applications and examples	132
5.4	Conclusion	137
	Acknowledgements	137
	References	137
6	Modification of measles virus and application to pathogenesis studies	150
	<i>Linda J. Rennick and W. Paul Duprex</i>	
6.1	Introduction	150
6.2	Measles: the disease	150
6.3	Measles: the infectious agent	151
6.4	RNA synthesis: a tail of two processes	154
6.5	Transcription: starting, stopping, dropping off or starting again	154
6.6	From transcription to replication: the elusive switch	155
6.7	Getting in and getting out	157

6.8	Measles virus: reverse genetics	158
6.9	Future perspectives	181
	Acknowledgements	182
	References	182
7	Bunyavirus reverse genetics and applications to studying interactions with host cells	200
	<i>Richard M. Elliott</i>	
7.1	Introduction: the family <i>Bunyaviridae</i>	200
7.2	Bunyavirus replication	201
7.3	History of bunyavirus reverse genetics	203
7.4	Minigenome systems for bunyaviruses	205
7.5	Virus-like particle production	207
7.6	Rescue systems for bunyaviruses	208
7.7	Application of reverse genetics to study bunyavirus replication	208
7.8	Outlook	215
	References	216
8	Using reverse genetics to improve influenza vaccines	224
	<i>Ruth A. Elderfield, Lorian C.S. Hartgroves and Wendy S. Barclay</i>	
8.1	Introduction	224
8.2	Influenza vaccines	227
8.3	The use of reverse genetics to generate recombinant influenza A, B and C viruses	229
8.4	Using reverse genetics technology for generation of pandemic virus vaccine	232
8.5	Other strategies for generating live attenuated vaccines based on viruses engineered by reverse genetics	235
8.6	Strategies to improve the safety or yield of influenza vaccines	238
8.7	Improvements to the PR8 high growth strain	239
8.8	Improving the immunogenicity by engineering recombinant viruses that express cytokine genes	240
8.9	Novel species-specific attenuation that takes advantage of microRNAs	240
8.10	Conclusion	241
	References	241
Part III	Double-stranded RNA viruses	251
9	Bluetongue virus reverse genetics	253
	<i>Mark Boyce</i>	
9.1	Introduction to Bluetongue virus	253
9.2	Bluetongue virus replication	254
9.3	Reverse genetics	260
9.4	Uses of reverse genetics in orbivirus research	271
9.5	Future perspectives	278
	References	281

10	Genetic modification in mammalian orthoreoviruses	289
	<i>Sanne K. van den Hengel, Iris J.C. Dautzenberg, Diana J.M. van den Wollenberg, Peter A.E. Sillevs Smitt and Rob C. Hoeben</i>	
10.1	Introduction	289
10.2	Forward-genetics in orthoreoviruses	296
10.3	Reovirus/cell interactions	297
10.4	Reverse-genetics in orthoreoviruses	301
10.5	Reovirus as an oncolytic agent	306
10.6	Conclusion	308
	References	309
Part IV	Recent and future developments	319
11	Reverse genetics and quasispecies	321
	<i>Antonio V. Bordería and Marco Vignuzzi</i>	
11.1	Definition of quasispecies and evidence	321
11.2	Reverse genetics and RNA virus population heterogeneity: consensus is always a compromise	328
11.3	Examples of the use of the theory to disable or manipulate the quasispecies under controlled environments	333
11.4	Future prospects of virus population genetics and reverse genetics	339
11.5	Conclusion	341
	References	342
12	Summary and perspectives	350
	<i>Anne Bridgen</i>	
12.1	Introduction	350
12.2	Analysis of the role of specific non-coding sequence motifs involved in replication, transcription, polyadenylation and packaging	351
12.3	Analysis of the roles of viral proteins	352
12.4	Analysis of virus–host interactions at a global level	353
12.5	Understanding the basis of pathogenicity	354
12.6	Real-time virus imaging <i>in vitro</i> and <i>in vivo</i>	355
12.7	Structure–function analysis of viruses and viral domains	356
12.8	Vaccine generation	357
12.9	Drug development	359
12.10	Gene delivery and knock-out in plant cells including virus-induced gene silencing (VIGS)	361
12.11	Gene delivery in arthropod and mammalian cells	362
12.12	Development of oncolytic virus and adaptation to this purpose	363
12.13	Personal highlights and future directions	364
	References	366
	Index	375